Hvilken er prisen på Celltrion, Inc. (068270)

Prisen på Celltrion, Inc. (068270) er $132.08

Hva er markedsverdien på Celltrion, Inc. (068270)

Markedsverdien på Celltrion, Inc. (068270) er $30.29B

Celltrion, Inc. (068270) Utestående Aksjer

Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.

År	Utestående aksjer	Endre
Ikke nok data for de angitte datoene.

År

Utestående aksjer

Endre

Ikke nok data for de angitte datoene.

Selskap	Utestående aksjer	Forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	478.91M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

Selskap

Utestående aksjer

Forskjell

Land